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Abstract
Objective: Our previous study suggested the potential clinical implications of BCAR1 in non-small-cell lung cancer (NSCLC)
(Mol Diagn Ther. 2011. 15(1): 31–40). Herein, we aim to evaluate the predictive power of BCAR1 as a marker for poor
prognosis in NSCLC cases, verify the carcinogenic roles of BCAR1 in the A549 lung adenocarcinoma cell line, and testify to
the BCAR1/phospho-p38 axis.
Methods: Between January 2006 and June 2010, there were a total of 182 patients with NSCLC (151 cases with available
follow up data, and 31 cases lost to follow-up due to the invalid contact information). We inspected BCAR1, phospho-
BCAR1(Tyr410), phospho-p38(Thr180/Tyr182) and p38 expression in NSCLC tissues and matched adjacent normal tissues by
immunoblotting and IHC. After BCAR1 -RNA interference in A549 cells, we inspected the protein expression (BCAR1,
phospho-BCAR1, phospho-p38 and p38) and performed cell biology experiments (cell growth, migration and cycle).
Results: BCAR1 was overexpressed in NSCLC tissues (177/182) and cell lines (A549 and Calu-3). However, it was not detected
in the normal adjacent tissue in 161 of the 182 cases. Higher BCAR1 levels were strongly associated with more poorly
differentiated NSCLC and predicted poorer prognosis. BCAR1 knockdown caused cell growth arrest, cell migration inhibition
and cell cycle arrest of A549 cells. Overexpression of BCAR1 was associated with activation of p38 in NSCLC cases, and
BCAR1 knockdown caused reduction of phospho-p38 levels in A549 cells.
Conclusion: Overexpression of BCAR1 is a predictor of poor prognosis in NSCLC and plays important carcinogenic roles in
carcinogenesis, probably via activation of p38 MAPK. However, further investigations are required immediately.
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Introduction
Every year, there are 1.35 million new lung cancer cases in the
world [1]. Worldwide, Lung cancer is the leading cause of cancer-
related deaths [2]. Due to the intricate biological functions,
prognosis of lung cancer remains very poor [1]. Hence, it is vital to
unveil the biological functions of the disease for the sake of
improving therapeutic efficacy [3].
Breast cancer anti-estrogen resistance 1 (BCAR1), also entitled
p130cas, was one of the CAS protein (Crk-associated substrate)
family members. It was originally identified as a cellular protein
migrating at 130 kDa, and to be hyperphosphorylated in v-Crk
and v-Src transformed cells [4,5]. Initially, intensive studies were
focused on the correlation between breast cancer and BCAR1
[6,1,7,8]. For instance, Brinkman et al. [7] suggested BCAR1
overexpression in ZR-75-1 breast cancer cell line renders
antiestrogen resistance to the cells. Furthermore, Dorssers et al.
[8] reported that BCAR1 expression was inversely related to
relapse-free survival and overall survival time of breast cancer.
Recently, our study suggested there is a clinical implication of
BCAR1 in non-small-cell lung cancer (NSCLC) [9]. We
investigated serum BCAR1 levels in 80 NSCLC cases and 80
healthy controls, respectively, by using a specific enzyme-linked
immunosorbent assay (ELISA) [9]. Intriguingly, we found that
serum BCAR1 levels were significantly higher in NSCLC than in
the control group, increased gradually with the progression of
tumor staging, and decreased after removal of the malignant
lesions [9]. However, the oncogenic mechanisms of BCAR1 in
NSCLC are still the enigmas.
Herein, we conducted the further investigations to evaluate the
predictive power of BCAR1 as a biomarker for poor prognosis in
NSCLC patients. And we verified the carcinogenic roles of
BCAR1 via RNA interference (RNAi) in A549 lung adenocarci-
noma cell line. Experiments in vivo and vitro demonstrated the
closed correlation between BCAR1 expression and activation of
p38 which is a crucial branch of the MAPK (mitogen-activated
protein kinase) pathway [10,11].
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Patients
The study protocol was reviewed and approved by the Research
Ethics Board in Daping hospital (Chongqing City, P.R.China)
[reference no. TMMU-DPH/2006-012], and informed consent
was written and obtained from all the patients.
In the study performed between January 2006 and June 2010,
there were a total of 182 patients with NSCLC. Pulmonary
neoplasm was diagnosed radiographically and confirmed by
pathology. None of the patients had received treatment before
enrollment in the study. The demographic and clinicopathological
characteristics of patients are shown in table 1. All the patients
underwent lobectomy and lymphadenectomy. One hundred and
thirty five patients received postoperative adjuvant chemotherapy
(Paclitaxel plus Nedaplatin). Postoperative follow-up was available
in 151 cases by telephone or letter interview, and 31 cases lost to
follow-up due to the invalid contact information.
Cell Culture
A549 and Calu-3 lung adenocarcinoma cell lines were obtained
from the American Type Culture Collection and cultured in
RPMI1640/10% FBS, respectively.
RNA Interference of BCAR1
Firstly, the following oligoribonucleotide pairs were used: 59-
CCGGGGTCGACAGTGGTGTGTATTTCAAGAGAATAC-
ACACCACTGTCGACCTTTTTTg-39 and 59-AATTCAAAA-
AAGGTCGACAGTGGTGTGTATTCTCTTGAAATACACA-
CCACTGTCGACC-39. Entire sequences were derived from the
sequence of human BCAR1 mRNA. The oligonucleotides were
obtained from Sunbio Medical Biotechnology CO., Ltd (Shanghai
City, P.R.China). The complementary two strands (each at
20 mM) in 60 ml of annealing buffer (Sunbio Medical Biotechnol-
ogy CO., Ltd, Shanghai City, P.R.China) were heated for 5 min
at 95uC and then incubated for 1 h at room temperature.
Thereafter, the GFP-tagged lentiviral vector pLVT351.LV for
BCAR1-RNAi was constructed by inserting the annealing
Table 1. The patients’ clinical and pathological characteristics according to BCAR1 and p-p38 expression in NSCLC.
Characteristics No. BCAR1 p-p38
2 + ++ +++ P 2 + ++ +++ P
Group
NSCLC 182 5 75 60 42 0.000# 101 36 32 13 0.000#
Normal tissue 182 156 26 0 0 148 32 2 0
Age
,60 78 3 31 30 14 0.507* 49 12 12 5 0.129*
$60 104 2 44 30 28 52 24 20 8
Gender
Female 56 1 16 22 17 0.16* 31 11 7 7 0.792*
Male 126 4 59 38 25 70 25 25 6
Histology
squamous cell carcinoma 115 4 51 37 23 0.11* 68 20 20 7 0.242*
adenocarcinomas. 67 1 24 23 19 33 16 12 6
Differentiation
Well 63 0 37 18 8 0.010n 37 11 11 4 0.665n
Moderately 97 4 32 34 27 53 20 17 7
Poorly 22 1 6 8 7 11 5 4 2
TNM stage
I 41 0 21 16 4 0.241n 23 7 8 3 0.889n
I I 9 1 3 3 5 3 02 3 4 8 2 21 47
III 47 2 17 13 15 28 7 9 3
IV 3 0 2 1 0 2 0 1 0
lymphonode status
N0 128 4 54 40 30 0.711* 71 24 23 10 0.818*
N1–N3 54 1 21 20 12 30 12 9 3
Tumor size
,3 cm 101 3 48 26 24 0.206* 57 21 16 7 0.523*
$3 cm 81 2 27 34 18 44 15 18 6
Note:
#: X
2 test for the positive rate of staining (NSCLC vs Normal adjacent tissue);
*: Mann-whitney U test;
n: Kruskal-Wallis test.
doi:10.1371/journal.pone.0036124.t001
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Medical Biotechnology CO., Ltd, Shanghai City, P.R.China).
Secondly, A549 cell line was plated at 2.3610
5 cells per well of
24-well cell culture plate and infected with lentivirus at a
multiplicity of infection (MOI) of 10. Cells infected with
pLVT351-L.V. and CMV-GFP-L.V.(blank lentiviral vector,
pMAGic 4.1) was named as A549-BCAR1-RNAi and A549-
negative control, respectively.
Western Blotting analysis of BCAR1, phospho-BCAR1,
phospho-p38 and p38 in NSCLC tissues and cells
NSCLC and matched adjacent normal tissues (at least 5 cm
away from the primary tumors) were available from a total of sixty
(including 35 adenocarcinomas and 25 squamous cell carcinomas)
cases for western blotting. During the operations, the samples were
collected by the technicians promptly following removals. Besides,
we also prepared the cell lines including Calu-3, A549, A549-
negative control and A549-BCAR1-RNAi.
Thereafter, lysates from tissues and cell lines were prepared in a
RIPA buffer comprising 50 mM Tris–HCl pH 7.5, 150 mM
NaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid and
0.02% sodium azide. The protein concentrations were determined
with a BCA Protein Assay Kit (Pierce, Rockford, IL).
Proteins were denatured at 95uC for 5 min, and 50 mg protein
per lane was resolved by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) using 10% polyacrylamide gel.
Proteins were blotted on polyvinylidene difluoride (PVDF)
membranes (Thermo), which were then blocked with 5% skim
milk for 1 h at room temperature. The proteins were immuno-
blotted using anti-BCAR1 antibody(BD Transduction Laborato-
ries, USA, 1:1000), anti-phospho-BCAR1 (Tyr410) antibody
(Abcam, USA, 1:1000), anti-p38 (BD Transduction Laboratories
material, USA, 1:1000) and anti-phospho-p38(Thr180/Tyr182)
antibody (cell signaling Transduction Laboratories, USA, 1:1000).
An anti-b-actin(Sigma) or GAPDH (Sigma) antibody served as the
control.
Gray scales of immunoblotting of NSCLC and matched
adjacent normal tissues were quantitatively analyzed by using
image acquisition and analysis software (Image Lab software, BIO-
RAD, USA) according to the manufacturer’s instructions.
Tissue microarray construction and
Immunohistochemical (IHC) assay of BCAR1, phospho-
BCAR1, p38 and phospho-p38 in NSCLC tissues
The hematoxylin and eosin (H&E)-stained slides of all 182 cases
were inspected. For each case, the pathologic diagnosis was
identified on the H&E-stained slide and then circled. A
corresponding slide of normal adjacent tissue was also marked.
Tissue microarray was constructed according to the previously
published protocols [9]. The marked slide was aligned with the
surface of the corresponding donor block. Thereafter, the area was
marked on the paraffin tissue blocks. From each specimen, tissue
cores with a diameter of 1.5 mm were punched and then arrayed
on a recipient paraffin block. Sections (4 mm) of these microarray
blocks were cut and then used for the IHC analysis.
The sections were incubated with serum blocking solution and
primary antibodies including anti-BCAR1 antibody (BD Trans-
duction Laboratories, USA, 1:100), anti-phospho-BCAR1
(Tyr410) antibody (Abcam, USA, 1:100), anti-p38 antibody (BD
Transduction Laboratories, USA, 1:50) and anti-phospho-p38
(Thr180/Tyr182) antibody (cell signaling Transduction Labora-
tories, USA, 1:10), biotinylated secondary antibody, and strepta-
vidin-horseradish peroxidase. Diaminobenzidine solution was used
as a chromogen. The slides were then counterstained in a
hematoxylin solution. The IHC results on protein abundance were
classified according to the percents of positive cells as follows: 2,
negative staining; +, weak position (,25%); ++, moderate position
(,50%); +++, strong position ($50%). ‘‘,25%’’ was classified as
low expression, otherwise as high expression. Three observers
carried out to score the slides and mean values were obtained
finally.
TDT-mediated dUTP nick end labeling assay (TUNEL) of
NSCLC tissues
We conducted TUNEL assay in tissue sections of all the 182
cases. Apoptosis in the tumor was inspected with In Situ Cell
Death Detection kit, POD (Roche, Germany). Tissue sections
were deparaffinize in xylene, and hydrated through graded
ethanol and pretreated with microwave antigen retrieval (citrate
buffer, pH 7.5). Endogenous peroxidase was blocked by 0.3%
H2O2 in methanol for 15 min. Thereafter, tissue sections were
treated with 3% bovine serum albumin for 30 min and incubated
with TUNEL reaction mixture (TDT : dUTP, 1:20) for 45 min at
37uC. Tissue sections were combined with Converter-POD,
followed by washing and DAB (Zhong Shong, China) color
reaction. During the TUNEL procedure, sections were washed in
phosphate buffer saline (PBS). Tissue sections were counterstained
by hematoxylin, dehydrated through graded ethanol, cleared in
xylene, and mounted. For negative controls, deionized water was
used instead of TDT. Positive controls consisted of inflamed
human tonsil. Cells were considered positive when intense brown
reactivity was detected in the nuclei. Apoptotic index was
calculated the percentage of nuclear positive stain in 1000 cells
in five different sites of each section at a 4006magnification.
Real-time RT-PCR
To evaluate the efficacy of RNAi of BCAR1, we performed
quantitative real-time RT-PCR in A549-BCAR1-RNAi and
A549-negative control cells. Either of the cells was seeded at a
concentration of 1610
5cells/well in 6-well plates. After two days
seeding, total RNA was extracted from cells using Trizol reagent
(Invitrogen). First-strand cDNA was synthesized with M-MLV
transcriptase (Promega) and oligo dT. Real-time PCR was
performed using SYBR Green PCR master mix (TAKARA) and
the ABI Prism 7000 sequence detection system (Applied
Biosystems, Foster City, CA). PCR primers were used as
followings: 59-CAATGCCTCACTGCTCTT-39 and 59-GTAGT-
CATAGTCCTCCATC-39. The specificity of detected signals was
confirmed by a dissociation curve consisting of a single peak. All
samples were run in duplicate in each experiment. Values were
normalized by human b-actin.
Cell Growth Assay
For evaluation of cell growth, A549-negative control and A549-
BCAR1-RNAi cells was plated at 2.0610
2 cells per well in six-well
plates, respectively. And either of the cells was inspected and
photographed following Giemsa staining, eleven days after plating.
Cell Migration Assay
For assessment of cell motility, chamber migration assays were
conducted using a cell culture insert (8-mm pore size, 24-well
format; Cell Invasion Assay Kit Cat. CHEMICON,
No. ECM550). A549-negative control and A549-BCAR1-RNAi
cells were seeded in duplicate at a density of 3.0610
5 cells/
chamber. After 48 hours, cells which had not moved to the lower
wells were removed from the upper face of the filters using cotton
BCAR1 in NSCLC
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were stained by using a Cell Invasion Assay Kit Cat. (CHEMI-
CON, No. ECM550). Cell migration was quantified by visual
counting after being photographed. Experiments were performed
in duplicate. Mean values for three random fields were obtained
for each well.
Cell Cycle Assays
For flow cytometric determination of cell cycles, 2.0610
6 of
A549-negative control cells and A549-BCAR1-RNAi cells were
fixed in 70% ethanol and stained with propidium iodide,
respectively. The stained cells were analyzed on a FACScan flow
cytometer for relative cell cycles. Experiments were performed in
duplicate.
Cell Apoptosis Assays
We evaluated cell apoptosis using FACScan flow cytometer.
2.0610
6 of A549-negative control cells (48 h after transient
transfection), A549-negative control cells (stable transfection),
A549-BCAR1-RNAi cells (48 h after transient transfection) and
A549-BCAR1-RNAi cells (stable transfection) were fixed in 70%
ethanol and stained with propidium iodide, respectively. The
stained cells were analyzed on a FACScan flow cytometer for
relative cell apoptosis. Experiments were performed in duplicate.
Data Analysis
The statistical analysis was performed using the Student’s t-test,
Mann-whitney U test, Kruskal-Wallis test, X
2 test and Spearman’s
rho, respectively. Death from any cause was included in the
calculation of postoperative survival. The disease specific survival
was calculated by the Kaplan-Meier method and analyzed by the
log-rank test. Prognostic factors were examined by univariate and
multivariate analyses using a Cox proportional hazards model. All
of the aforesaid calculations were performed using SPSS Version
11.0 software for Windows (SPSS, Inc., Chicago, USA). A value of
p,0.05 (two-sided) was considered statistically significant.
Results
BCAR1 is overexpressed in NSCLC tissues and cell lines
BCAR1 expression was detected (either in the nucleus, the
cytoplasm, or both) in 57 of the 60 NSCLC cases by using
Immunoblotting (Figure 1a), and 177 of the 182 NSCLC cases by
using IHC assay(Figure 1c), respectively. However, it was not
detected in the normal adjacent tissue in 53 of the 60 cases by
using Immunoblotting (Figure 1a), and 161 of the 182 cases by
using IHC assay (Figure not shown), respectively. Analysis of gray
scales of immunoblotting also suggested BCAR1 levels were
significantly higher in NSCLC than in the normal adjacent tissue
(48.2624.7 vs 11.069.8, Student’s t-test, P,0.001, Figure 1b).
However, phospho-BCAR1(Tyr410) was detected in cytoplasm
in 29 of the 60 NSCLC by using Immunoblotting (Figure 1a), and
32 cases of the 182 NSCLC cases by using IHC assay(Figure 1c),
respectively. However, it was also detected in the normal adjacent
tissue in 30 of the 60 cases by using Immunoblotting (Figure 1a),
and 34 of the 182 cases by using IHC assay (Figure not shown),
respectively. Analysis of gray scales of immunoblotting suggested
there was no appreciable difference of BCAR1 levels in between
NSCLC and the normal adjacent tissue (25.3611.2 vs 27.8615.2,
P=0.476, Student’s t-test, Figure 1b).
BCAR1 and phospho-BCAR1(Tyr410) was detected in A549
and Calu-3 NSCLC cells by using immunoblotting assay
(Figure 1a).
Higher BCAR1 levels are strongly correlated with more
poorly differentiated tumors and predicts poorer
prognosis
By using IHC assay in the 182 NSCLC cases, we found that
higher BCAR1 levels were strongly correlated with more poorly
differentiation. (Kruskal-Wallis test, P=0.01; Table 1). However,
there was no appreciable correlation between BCAR1 and other
clinical-pathological characteristics including age, gender, histol-
ogy, TNM stage, tumor size and lymphonode metastasis (Table 1).
Despite BCAR1 expression was detected either in cytoplasm,
nucleus, or both in NSCLC, there was no appreciable correlation
between the protein location and clinical-pathological parameters
(Data not shown). Besides, there was no significant correlation
between phospho-BCAR1 and the clinical-pathological character-
istics (Data not shown).
The survival rate of BCAR1 high-expression group was
significantly lower than of low-expression group (P=0.001,
Figure 2a). Multivariate analysis revealed that BCAR1 levels
(hazard ratio 1.777, P=0.028), lymphonode metastasis (hazard
ratio 1.277, P=0.040) and TNM stage (hazard ratio 1.298,
P=0.007) were significant and independent prognostic indicators
for NSCLC cases (Table 2).
BCAR1 knockdown causes cell growth arrest, cell
migration inhibition and cell cycle arrest of A549 cells
We established human NSCLC cancer A549 cells that stably
expressed pLVT351-L.V. (A549-BCAR1-RNAi cells) and CMV-
GFP-L.V. (A549-negative control cells) through use of a lentivirus
system. At least an 80% reduction in mRNA levels of BCAR1 in
A549-BCAR1-RNAi cells was confirmed by real-time RT-PCR
(Figure 3a) and Western Blotting analysis (Figure 1a), respectively.
Simultaneously, we can see the inhibition of phospho-BCAR1
along with BCAR1 knockdown (Figure 1a).
Figure 3b suggested colony forming units of A549-BCAR1-
RNAi cells were detectably less than of A549-negative control
cells, eleven days after plating (Figure 3b). Cell migration assay
suggested BCAR1 knockdown prevented cell migration of A549-
BCAR1-RNAi cells (Figure 3c). And Flow cytometry indicated
BCAR1 knockdown also caused cell cycle arrest of A549-BCAR1-
RNAi cells (Figure 3d).
BCAR1 is adversely correlated to apoptotic index in
NSCLC tissues. However, BCAR1 knockdown can not
increase apoptosis in A549 cells
Apoptotic bodies were detected in all the 182 NSCLC tissues
(Figure 1c). Among the tissues, there was a significant and inverse
correlation between BCAR1 and apoptotic index (Spearman’s
rho, correlation coefficient=20.183; P=0.013). Apoptotic index
in BCAR1 high-expressed tissues was substantially lower than in
BCAR1 low-expressed tissues (Student’s t-test t=2.312 P=0.022).
However, in comparison with negative control cells, BCAR1
knockout did not increase apoptosis rate following either transient
(39.1% vs 42.1%) or stable transfection (0.33% vs 0.4%) in A549
cells (Figure 3e).
Overexpression of BCAR1 is correlated with activation of
p38 in NSCLC cases and BCAR1 knockdown causes
reduction of phospho-p38 in A549 cells
Phospho-p38 expression was detected in 31 of the 60 NSCLC
cases by using immunoblotting (Figure 1a), and 91 of the 182
NSCLC cases (prone to locate in the nucleus) by using IHC assay
(Figure 1c). Similar to the trend of BCAR1 levels, gray scales
BCAR1 in NSCLC
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NSCLC than in the normal adjacent tissues (16.0365.8 vs
28.8268.0, P,0.001; Figure 1b). However, p38 had not the trend
(20.7266.4 vs 24.3767.5, P=0.22) (Figure 1b). Besides, IHC
suggested positive rate of either BCAR1 or phospho-p38 was
substantially higher in NSCLC than in normal tissue (P,0.001
and P,0.001, respectively) (table 1). However, p38 had not such
trend (P=0.62).
We found percentages of phospho-p38 positive cells was
significantly and positively correlated with those of BCAR1
positive cells, in all the 182 NSCLC tissues (Spearman’s rho,
correlation coefficient=0.811, p,0.001; Figure 2b). And percent-
ages of phospho-p38 positive cells in BCAR1 high-expressed
tissues were significantly higher than in BCAR1 low-expressed
tissues (Mann-whitney U test z=23.689 P,0.001; Figure 2b).
However, there was not any correlation between phospho-BCAR1
and phospho-p38 levels (P=0.892).
In an attempt to depict the strong correlation between BCAR1
positive and phospho-p38 positive cells, we presented the
sequential sections stained in one case for BCAR1, phospho-
BCAR1, phospho-p38 and p38, which demonstrated that the cells
over-expressing BCAR1 also have a higher level of phospho-p38
(Figure 2c).
BCAR1 levels in Calu-3 cells were detectably higher compared
with A549 cells (Figure 1a). Intriguingly, Figure 1a suggested
phospho-p38 levels also had the same trend. Furthermore,
BCAR1 knockdown also causes the appreciable reduction of
phospho-p38 abundance in A549 cells (Figure 1a).
Discussion
BCAR1 as an adapter protein localizes to chromosome 16q22-
q23
7, and mainly consists of four functional portions including an
amino-terminal Src homology 3 (SH3) domain, a Src-binding
Figure 1. BCAR1, phospho-BCAR1, p38 and phospho-p38 expression in NSCLC tissues and cells. A: Immunoblotting indicated either
BCAR1 or phospho-p38(Thr180/Tyr182) levels in three NSCLC tissues (C) were significantly higher than in the adjacent normal tissues (N). But
phospho-BCAR1 (Tyr410) and p38 levels in NSCLC and the adjacent normal tissues were similar. BCAR1, phospho-BCAR1, p38 and phospho-p38
expressions were also detected in A549 and Calu-3 NSCLC cell line by using Immunoblotting assay. BCAR1 knockdown causes the appreciable
reduction of phospho-BCAR1 and phospho-p38 levels in A549 cells. B: Gray scales analysis of immunoblotting also suggested BCAR1 and phospho-
p38(Thr180/Tyr182) levels were significantly higher in NSCLC than in the normal adjacent tissue (48.18624.7 vs 10.9769.8,P,0.001; 16.0365.8 vs
28.8268.0, P,0.001). However, phospho-BCAR1 (Tyr410) and p38 had not the trend (20.7266.4 vs 24.3767.5, P=0.22; 25.3611.2 vs 27.8615.2,
P=0.476). C: IHC suggested the expressions of BCAR1 (either in the nucleus, the cytoplasm), phospho- BCAR1 (prone to locate in the cytoplasm),
phospho-p38 (prone to locate in the nucleus), p38 (prone to locate in the cytoplasm) and apoptotic bodies. Note: N (adjacent normal tissue); C
(NSCLC tissue); ** (P,0.001); # (P.0.05).
doi:10.1371/journal.pone.0036124.g001
BCAR1 in NSCLC
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helix domain (HLH) [12,13]. BCAR1 locates ubiquitously in vitro
and vivo [14,15,16], and is involved in various cellular processes
including migration, chemotaxis, apoptosis, cell cycle, differenti-
ation and so forth [17,18].
Thus far, very few studies focused on the carcinogenesis of
BCAR1 in lung cancer. Wei et al. [19] suggested that anchorage-
independent phosphorylation of BCAR1 protected lung adeno-
carcinoma cells from anoikis. Recently, our study suggested that
serum BCAR1 levels were significantly higher in NSCLC than in
the control group, increased gradually with the progression of
tumor staging, and decreased after removal of the malignant
lesions [9]. As a result, we presumed a novel oncogenic role of
BCAR1 in NSCLC. Herein, we aimed to verify the clinical
implications of BCAR1 overexpression and NSCLC, and to
elucidate the carcinogenetic mechanisms of BCAR1 in NSCLC.
As expected, we found BCAR1 protein is especially abundant in
NSCLC cells and tissues. And our studies in vivo and vitro showed
the close correlation between BCAR1 expression and activation of
p38 MAPK. Although prior studies have shown that tyrosine
phosphorylation of BCAR1 can be critical for downstream
signaling [20], our study indicated that phospho-BCAR1(Tyr410)
was detected in only 34 of the 182 cases, and not correlated with
clinical-pathological characteristics. Thus far, numerous sites of
human BCAR1 phosphorylation are found as: tyrosine residues aa
12, 128, 165, 192, 222, 224, 234, 249, 267, 287, 306, 327, 362,
372, 387, 410, 653, 664, 666; serine residues aa 134, 139, 292,
437, 639; and threonine residues aa 269, 326, 385. We presume
that some specific sites of phosphorylation are critical for the signal
cascades of BCAR1 in NSCLC. Intriguingly, adjacent normal
tissues show much higher levels of phospho-BCAR1 than of
BCAR1 proteins (Figure 1a). We also confirmed the inhibition of
phospho-BCAR1 along with BCAR1 knockdown in an attempt to
verify the efficacy of this antibody. We presume that a special
enzyme in lung tissues specifically decomposes Non-phospho-
BCAR1, however, phospho-BCAR1 can survive. And all the
abovementioned hypotheses deserve further more investigations.
Our experiments in vitro demonstrated that BCAR1 knock-
down in A549 cells caused cell growth arrest, cell cycle arrest and
cell migration inhibition. Although BCAR1 knockdown in A549
Figure 2. High levels of BCAR1 predict poorer prognosis, and are correlated to activation of p38. A: The survival rate of BCAR1 high-
expressed group was significantly lower than of low-expressed group (P=0.001). B: Phospho-p38 positive cells was significantly and positively
correlated with percentages of BCAR1 positive cells, in the 182 NSCLC tissues (Spearman’s rho, correlation coefficient=0.811, p,0.001). And
percentages of phospho-p38 positive cells in BCAR1 high-expressed tissues were significantly higher than in low-expressed tissues (Mann-whitney U
test z=23.689 P,0.001). C: The sequential sections were stained for BCAR1, phospho-BCAR1, phospho-p38 and p38, which demonstrated that the
cells over-expressing BCAR1 also have a higher level of phospho-p38 (6200). Either phospho-BCAR1 or p38 was slightly positive.
doi:10.1371/journal.pone.0036124.g002
Table 2. Multivariate regression analysis in predicting the
overall survival of NSCLC patients.
Variable Hazard ratio
95% Cofidence
interval P-value
BCAR1 expressed levels 1.777 1.064–2.968 0.028
Phospho-BCAR1 levels 1.001 0.413–2.423 0.999
Age 0.960 0.643–1.433 0.843
Gender 0.778 0.493–1.225 0.278
Nodal status 1.277 1.018–1.668 0.040
Tumor size 1.113 0.748–1.655 0.597
Differentiation 1.449 0.753–2.794 0.267
TNM stage 1.298 1.068–1.588 0.007
Histology 1.103 0.689–1.543 0.882
doi:10.1371/journal.pone.0036124.t002
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inverse correlation between BCAR1 and apoptotic index in
NSCLC tissues. We do not know the reasons for discrepancy
between NSCLC cell and tissue. Additionally, our study in vivo
demonstrated that BCAR1 levels were significantly and inversely
correlated with tumor differentiation, by either counting positive
percents of cells (Kruskal-Wallis test, P=0.010) or evaluating
stained intensity (achromasy=0, stramineous=1, buffy=2,
brown=3; Kruskal-Wallis test, P=0.014). Kaplan-Meier curve
also indicated that higher levels of BCAR1 predicted poorer
Figure 3. In A549 cells, BCAR1 knockdown caused cell growth arrest, cell migration inhibition, cell cycle arrest, but not apoptosis. A:
At least an 80% reduction in mRNA of BCAR1 in A549-BCAR1-RNAi cells was confirmed by real-time RT-PCR. B: Colony forming units of A549-BCAR1-
RNAi were detectably less than of A549-negative control cells, eleven days after plating. C: Cell migration assay suggested BCAR1 knockout prevented
cell migration of A549-BCAR1-RNAi cells. D: Flow cytometry indicated BCAR1 knockout also caused cell cycle arrest of A549-BCAR1-RNAi cells. E: Flow
cytometry indicated BCAR1 knockout did not increase apoptosis rate following either transient (39.1% vs 42.1%) or stable transfection (0.33% vs
0.4%) in A549 cells.
doi:10.1371/journal.pone.0036124.g003
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aforementioned experiments suggested BCAR1 had a crucial role
in carcinogenesis. Besides, BCAR1 is known as Src substrate, and
Src inhibitor AZD0530 can also result in significant inhibition of
cell migration and matrigel invasion in lung cancer cells [21],
which potentially supports the carcinogenesis of Src/BCAR1 axis.
Using immunoblotting, Greenberg et al. [22] found that only
activated p38 MAPK was consistently increased in NSCLC in
comparison with normal tissue, suggesting an additional role for
this pathway in malignant cell growth or transformation. Indeed,
numerous studies had unveiled the carcinogenetic activities of p38,
including stimulation of proliferation and migration [1,23,24].
Matsuda K et al. [23] found that EGF promotes proliferation via
p38 MAPK signaling cascades in ASPC-1, PANC-1 and T3M4
pancreatic cancer cell lines, and p38 MAPK inhibitor SB203580
can inhibit EGF-stimulated mitogenesis. Besides, the p38 MAPK
pathway has been implicated to play an important role in
endothelial cell migration because inhibiting p38MAPK activity
down-regulates VEGF-stimulated migration [24]. Recently,
Wendt et al.’s study [25] demonstrated that increasing expression
of either the full-length or just the carboxyl terminus of BCAR1 in
mammary epithelial cells increased p38 activation. Intriguingly, in
182 NSCLC tissues, we found there was a close correlation
between the expression of BCAR1 and phospho-p38. By
evaluating stained intensity of phospho-p38 and BCAR1 (achro-
masy=0, stramineous=1, buffy=2, brown=3, ‘‘,2 scores’’ were
classified as low expression, otherwise as high expression), we
found the abundance of phospho-p38 was also significantly and
positively correlated with that of BCAR1 (Spearman’s rho,
p,0.001). Besides, BCAR1 knockdown also caused the apprecia-
ble reduction of phospho-p38 levels in A549 cells. However, the
underlying mechanisms deserve further investigations. Addition-
ally, Figure 1a demonstrated BCAR1 knockdown slightly
decreased expression of total p38 in A549 cells. Furthermore,
adjacent normal tissues had low BCAR1, but not a decreased level
of total p38. We think that the expression of total p38 is regulated
by the other signal cascades except for BCAR1 in NSCLC.
Collectively, BCAR1 is associated with poor prognosis of
NSCLC patients. BCAR1 knockdown experiments in A549 cells
strongly supported the carcinogenesis of BCAR1 in NSCLC,
probably via the activation of p38 MAPK. And we presume
BCAR1 may be a potential therapeutic target for NSCLC.
However, the further investigations are required immediately as:
(i)Mechanistic link between BCAR1 and phospho-p38 should be
studied; (ii) Stronger evidence should be provided to verify
carcinogenesis of BCAR1 through activation of p38; (iii) The
other key signaling molecules altered or activated by BCAR1,
other than p38, should be evaluated.
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